Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

The vascular micromilieu in obstructive sleep apnoea

R. Schulz
European Respiratory Journal 2005 25: 780-782; DOI: 10.1183/09031936.05.00022905
R. Schulz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Obstructive sleep apnoea (OSA) is increasingly recognised as an important cardiovascular risk factor. In particular, OSA has been shown to increase the risk of diurnal arterial hypertension in a dose-dependent manner, and is now considered as one of the most common causes of secondary arterial hypertension 1, 2. Furthermore, OSA increases the likelihood of developing vaso-occlusive disease, notably myocardial infarction and stroke, although this association seems to be weaker than that observed for arterial hypertension 3. Of note, the epidemiological studies demonstrating a genuine relationship between OSA and cardiovascular disorders have been controlled with respect to confounding factors such as age, body weight and metabolic disease.

How does one explain the causal link between OSA and cardiovascular disease? The repetitive collapse of the upper airway during sleep generates a unique pattern of hypoxia, with frequent cycles of hypoxia and re-oxygenation during the night, and a constant normoxia while awake. Accumulating evidence suggests that this chronic intermittent hypoxia causes a specific disturbance in the vascular micromilieu, with vasoconstrictive, pro-inflammatory and pro-coagulant forces predominating. Finally, the disturbance in the vascular micromilieu leads to endothelial dysfunction in these patients 4. This reduction in endothelial-dependent vasorelaxation has been established as a pathogenic factor in both systemic arterial hypertension and atherosclerosis. Treatment of OSA by continuous positive airway pressure (CPAP) ventilation not only eliminates apnoeas and nocturnal oxygen desaturations, but also exerts cardio-protective effects. Thus, CPAP therapy has been demonstrated to “normalise” the vascular micromilieu, to restore endothelial function and to lower 24-h blood pressure 5, 6.

The disturbance in the vascular micromilieu in OSA is characterised by sympathetic activation, insulin resistance, increased oxidative stress and, possibly, a state of hypercoagulability. Sympathetic activation is indicated by increased plasma and urinary levels of adrenaline/noradrenaline, as well as enhanced muscle sympathetic nerve activity (as measured by peroneal nerve microneurography 7, 8). It is believed that sympathetic over-activity is mainly responsible for the development of arterial hypertension in OSA. Furthermore, as catecholamines increase glucose levels, sympathetic activation probably leads to insulin resistance in untreated OSA patients 9. Decreased insulin sensitivity itself may promote the emergence of arterial hypertension and atherosclerosis.

Oxidative stress is another major mechanism that may explain the increased cardiovascular morbidity and mortality observed in OSA. Direct evidence for increased oxidative stress in OSA comes from two studies reporting enhanced in vitro release of free oxygen radicals from isolated neutrophils and monocytes 10, 11. These radicals may lead to a breakdown of endothelial-derived nitric oxide and to exaggerated lipid peroxidation, since both phenomena occur in OSA 12, 13. These effects may subsequently promote blood pressure elevations and accelerated atherosclerosis in affected patients. Haemostatic alterations to the vascular micromilieu, for example enhanced platelet activation and an increase in plasma fibrinogen levels, have also been described in OSA (for review see 14) and may provide a further explanation for the high prevalence of vascular diseases in these patients.

More recent work suggests that OSA patients also suffer from vascular inflammation. This is supported by studies that report an increase in circulating levels of endothelial adhesion molecules (i.e. soluble intercellular adhesion molecules and soluble vascular cell adhesion molecules 15), cytokines (i.e. interleukin-1, -6 and -8 and tumour necrosis factor-α 16), matrix metalloproteinases 17 and acute phase proteins (i.e. highly sensitive C-reactive protein, serum amyloid-A 18, 19). Furthermore, in vitro experiments have delineated that monocytes and γδ-T-cells from OSA patients bind more tightly to layers of endothelial cells than those from control subjects 11, 20. Presumably, this effect is mediated by an upregulation of adhesion molecules on the surface of these cells. In addition, the same cells are more injurious to the cultured endothelium, probably through an enhanced production and release of the above-mentioned cytokines. Taken together, these changes may significantly contribute to the development of inflammation-driven atherosclerosis. Along these lines, some groups have reported that OSA patients have a greater intima-media-thickness of their common carotid arteries when compared with matched controls 21, 22. This parameter reflects the early stages of atherosclerosis and is viewed as an accurate predictor of overall cardiovascular risk.

The current report of Dyugovskaya et al. 23 in this issue of the European Respiratory Journal contributes a novel aspect to the ever-growing complex picture of the vascular micromilieu in OSA. In this study, the cytotoxicity of CD8+ T-lymphocytes against human umbilical vein endothelial cells was investigated in three different patient groups: untreated OSA patients; control subjects; and single-night CPAP-treated OSA patients. These cells displayed increased cytotoxicity in the untreated OSA group, whereas CPAP therapy resulted in a lower cytotoxic potential, which was comparable to that of the control group. The authors conclude that CD8+ T-lymphocytes also participate in inflammatory/immune mechanisms in OSA and that this may equally be related to atherogenic sequelae in these patients.

One may criticise the study as the OSA patients had accompanying diseases that could also impact on lymphocyte activity (i.e. arterial hypertension and ischaemic heart disease). However, statistical analysis demonstrated that the OSA and control groups did not significantly differ with regard to these co-morbidities. Finally, the fact that CD8+ T-lymphocyte cytotoxicity was lower in CPAP-treated OSA patients clearly argues against the view that the observed in vitro effects were due to confounding factors. A further possible limitation of the study may be that the effects of short-term CPAP therapy on CD8+ T-lymphocyte cytotoxicity were assessed in a different subset of OSA patients. However, some of the initially diagnosed, untreated OSA patients were re-investigated after several months of CPAP therapy and showed similar phenotypic and functional changes in their CD8+ T-lymphocytes. Thus, there is little doubt as to the significance of the findings of Dyugovskaya et al. 23.

What remains to be done? Future studies investigating vascular disease biomarkers and cell biology in OSA should preferably enrol otherwise healthy OSA patients and closely matched control groups. Furthermore, reversibility testing after CPAP therapy in these studies should be more refined (i.e. inclusion of short- and long-term observations, sham-CPAP arms and, possibly, measurements after CPAP withdrawal). Finally, changes in biomarkers and cell activity should be related to biological parameters of the cardiovascular system, for example blood pressure, intima-media-thickness or endothelial-dependent vasodilation.

Certainly, the basic mechanisms of the disturbance to the vascular micromilieu in OSA need to be further clarified. In this context, one feasible approach is to set up animal models of OSA-related cardiovascular disease, for example targeted deletion of candidate genes in experimental animals.

Regardless of these considerations, the data of Dyugovskaya et al. 23 and others lay important groundwork for the initiation of pharmacological intervention studies to prevent and/or treat the cardiovascular complications of obstructive sleep apnoea. Such studies may, for example, test the effects of antioxidants, nitric oxide donors and anti-inflammatory agents (i.e. statins, etc.). If these drugs prove beneficial, then they may be of special value in those obstructive sleep apnoea patients who discontinue or refuse continuous positive airway pressure therapy.

    • © ERS Journals Ltd

    References

    1. ↵
      Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000;342:1378–1384.
      OpenUrlCrossRefPubMedWeb of Science
    2. ↵
      Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289:2560–2572.
      OpenUrlCrossRefPubMedWeb of Science
    3. ↵
      Shahar E, Whitney CW, Redline S, et al. Sleep-disordered breathing and cardiovascular disease. Cross sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 2001;163:19–25.
      OpenUrlCrossRefPubMedWeb of Science
    4. ↵
      Carlson JT, Rangemark C, Hedner JA. Attenuated endothelium-dependent vascular relaxation in patients with sleep apnoea. J Hypertens 1996;14:577–584.
      OpenUrlCrossRefPubMedWeb of Science
    5. ↵
      Ip MS, Tse HF, Lam B, Tsang KW, Lam WK. Endothelial function in obstructive sleep apnea and response to treatment. Am J Respir Crit Care Med 2004;169:348–353.
      OpenUrlCrossRefPubMedWeb of Science
    6. ↵
      Becker HF, Jerrentrup A, Ploch T, et al. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation 2003;107:68–73.
      OpenUrlAbstract/FREE Full Text
    7. ↵
      Carlson JT, Hedner J, Elam M, Ejnell H, Sellgren J, Wallin BG. Augmented resting sympathetic activity in awake patients with obstructive sleep apnea. Chest 1993;103:1763–1768.
      OpenUrlCrossRefPubMedWeb of Science
    8. ↵
      Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest 1995;96:1897–1904.
    9. ↵
      Ip MS, Lam B, Ng MM, Lam WK, Tsang KW, Lam KS. Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med 2002;165:670–676.
      OpenUrlCrossRefPubMedWeb of Science
    10. ↵
      Schulz R, Mahmoudi S, Hattar K, et al. Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea. Impact of continuous positive airway pressure therapy. Am J Respir Crit Care Med 2000;162:566–570.
      OpenUrlCrossRefPubMedWeb of Science
    11. ↵
      Dyugovskaya L, Lavie P, Lavie L. Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. Am J Respir Crit Care Med 2002;165:934–939.
      OpenUrlCrossRefPubMedWeb of Science
    12. ↵
      Schulz R, Schmidt D, Blum A, et al. Decreased plasma levels of nitric oxide derivatives in obstructive sleep apnoea - response to CPAP therapy. Thorax 2000;55:1046–1051.
      OpenUrlAbstract/FREE Full Text
    13. ↵
      Lavie L, Vishnevsky A, Lavie P. Evidence for lipid peroxidation in obstructive sleep apnea. Sleep 2004;27:123–128.
      OpenUrlPubMedWeb of Science
    14. ↵
      von Kanel R, Dimsdale JE. Hemostatic alterations in patients with obstructive sleep apnea and the implications for cardiovascular disease - opinions/hypotheses. Chest 2003;124:1956–1967.
      OpenUrlCrossRefPubMedWeb of Science
    15. ↵
      Chin K, Nakamura T, Shimizu K, et al. Effects of nasal continuous positive airway pressure on soluble cell adhesion molecules in patients with obstructive sleep apnea syndrome. Am J Med 2000;109:562–567.
      OpenUrlCrossRefPubMedWeb of Science
    16. ↵
      Vgontzas AN, Papanicolaou DA, Bixler EO, Kales A, Tyson K, Chrousos GP. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J Clin Endocrinol Metab 1997;82:1313–1316.
      OpenUrlCrossRefPubMedWeb of Science
    17. ↵
      Tazaki T, Minoguchi K, Yokoe T, et al. Increased levels and activity of matrix metalloproteinase-9 in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2004;170:1354–1359.
      OpenUrlCrossRefPubMedWeb of Science
    18. ↵
      Shamsuzzaman AS, Winnicki M, Lanfranchi P, et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 2002;105:2462–2464.
      OpenUrlAbstract/FREE Full Text
    19. ↵
      Svatikova A, Wolk R, Shamsuzzaman AS, Kara T, Olson EJ, Somers VK. Serum amyloid a in obstructive sleep apnea. Circulation 2003;108:1451–1454.
      OpenUrlAbstract/FREE Full Text
    20. ↵
      Dyugovskaya L, Lavie P, Lavie L. Phenotypic and functional characterization of blood γδ-T cells in sleep apnea. Am J Respir Crit Care Med 2003;168:242–249.
      OpenUrlCrossRefPubMedWeb of Science
    21. ↵
      Silvestrini M, Rizzato B, Placidi F, Baruffaldi R, Bianconi A, Diomedi M. Carotid artery wall thickness in patients with obstructive sleep apnea syndrome. Stroke 2002;33:1782–1785.
      OpenUrlAbstract/FREE Full Text
    22. ↵
      Schulz R, Seeger W, Fegbeutel C, et al. Changes in extracranial arteries in obstructive sleep apnoea. Eur Respir J 2005;25:69–74.
      OpenUrlAbstract/FREE Full Text
    23. ↵
      Dyugovskaya L, Lavie P, Hirsh M, Lavie L. Activated CD8+ T-lymphocytes in obstructive sleep apnoea. Eur Respir J 2005;25:820–828.
      OpenUrlAbstract/FREE Full Text
    PreviousNext
    Back to top
    View this article with LENS
    Vol 25 Issue 5 Table of Contents
    • Table of Contents
    • Index by author
    Email

    Thank you for your interest in spreading the word on European Respiratory Society .

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    The vascular micromilieu in obstructive sleep apnoea
    (Your Name) has sent you a message from European Respiratory Society
    (Your Name) thought you would like to see the European Respiratory Society web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Print
    Citation Tools
    The vascular micromilieu in obstructive sleep apnoea
    R. Schulz
    European Respiratory Journal May 2005, 25 (5) 780-782; DOI: 10.1183/09031936.05.00022905

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

    Share
    The vascular micromilieu in obstructive sleep apnoea
    R. Schulz
    European Respiratory Journal May 2005, 25 (5) 780-782; DOI: 10.1183/09031936.05.00022905
    del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
    Full Text (PDF)

    Jump To

    • Article
      • References
    • Info & Metrics
    • PDF
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    More in this TOC Section

    • Improving IGRA interpretation: are IP-10 and MIG the solution?
    • CFTR: a missing link between smoking and chronic airway diseases?
    • Update March 2022: ERS guidelines for management of hospitalised COVID-19 patients
    Show more Editorials

    Related Articles

    Navigate

    • Home
    • Current issue
    • Archive

    About the ERJ

    • Journal information
    • Editorial board
    • Reviewers
    • Press
    • Permissions and reprints
    • Advertising

    The European Respiratory Society

    • Society home
    • myERS
    • Privacy policy
    • Accessibility

    ERS publications

    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS books online
    • ERS Bookshop

    Help

    • Feedback

    For authors

    • Instructions for authors
    • Publication ethics and malpractice
    • Submit a manuscript

    For readers

    • Alerts
    • Subjects
    • Podcasts
    • RSS

    Subscriptions

    • Accessing the ERS publications

    Contact us

    European Respiratory Society
    442 Glossop Road
    Sheffield S10 2PX
    United Kingdom
    Tel: +44 114 2672860
    Email: journals@ersnet.org

    ISSN

    Print ISSN:  0903-1936
    Online ISSN: 1399-3003

    Copyright © 2022 by the European Respiratory Society